SCHEMBL1970164

SCHEMBL1970164

COC(=O)C(C)(NCCCCO)c1ccc(O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.41
ESRRG P62508 5/20 0.37
ESRRB O95718 2/20 0.36
ESR1 P03372 2/20 0.36
CYP3A4 P08684 2/20 0.36
ESR2 Q92731 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
CHRM2 P08172 1/20 0.35
CNR1 P21554 1/20 0.35
LMNA P02545 1/20 0.34
TYR P14679 1/20 0.34
AR P10275 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
HTR6 P50406 1/20 0.34
SLC6A3 Q01959 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968656 0.96 ESRRG (0.38) POLBESRRGESRRBESR1CYP3A4
SCHEMBL1970358 0.90 ESRRG (0.38) POLBESRRGESRRBESR1CYP3A4
SCHEMBL1968275 0.79 ESR1 (0.37) ESRRGESRRBESR1CYP3A4ESR2
SCHEMBL1971759 0.77 POLB (0.40) POLBESR1CYP3A4ESR2ALDH1A1
SCHEMBL1969036 0.77 MAOB (0.39) ESRRGESRRBESR1CYP3A4ESR2
SCHEMBL1969109 0.75 PKM (0.39) ESRRGESRRBESR1CYP3A4ESR2
SCHEMBL1970446 0.75 ESR1 (0.43) ESRRGESRRBESR1CYP3A4ESR2
SCHEMBL29074073 0.70 ESR1 (0.42) ESRRGESRRBESR1CYP3A4ESR2
SCHEMBL834511 0.69 CHRM2 (0.53) ESRRGESR1CYP3A4ESR2ALDH1A1
SCHEMBL3573740 0.69 CNR1 (0.53) ESRRGESR1CYP3A4ESR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168667-B2 Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such GALAPAGOS NV (BE) 2012-05-01 US disclosed
EP-2026799-B1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH GALAPAGOS SAS (FR) 2011-06-22 EP disclosed
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH DART THERAPUTICS, LLC. 2010-08-19 US disclosed
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such SASU, GALAPAGOS (FR) 2010-03-11 US disclosed
EP-2026799-A2 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH Galapagos SAS (FR) 2009-02-25 EP disclosed
WO-2007137874-A2 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH GALAPAGOS SAS (FR) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH NR5A1, AR, HSD17B7 POLB 4342/4885ESRRG 246/4885ESRRB 53/4885
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such NR5A1, AR, HSD17B7 POLB 4363/4885ESRRG 246/4885ESRRB 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.